The biotech industry has been abuzz with the latest results from the testing of RegenxBio’s RGX-202. The promising outcomes from the study, reported in November 2024, highlight the treatment’s potential to enhance muscle function in patients, particularly in tasks like walking, rising, and stair-climbing. These positive results, based on improvements in muscle function in boys […]
Tag: Regenxbio
Otsuka’s Sibeprenlimab Outperforms Vera in Kidney Disease Study
In the competitive landscape of kidney disease treatments, Vera Therapeutics recently saw a significant decline in market value, triggered by Otsuka Pharmaceutical’s late-stage data presentation on sibeprenlimab, a rival drug for IgA nephropathy. Otsuka’s therapy showed a 51% reduction in proteinuria, a critical marker of kidney health, after nine months of treatment. In comparison, Vera’s […]